Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 7/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3615323 | 1.00 | CHRNA7 (0.43) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3614181 | 0.86 | CHRNA7 (0.46) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3614176 | 0.86 | CHRNA7 (0.46) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3616070 | 0.86 | CHRNA7 (0.43) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3611605 | 0.86 | CHRNA7 (0.43) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3619739 | 0.84 | CHRNA7 (0.47) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3615274 | 0.84 | CHRNA7 (0.47) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3618942 | 0.84 | MAPT (0.42) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3618937 | 0.84 | MAPT (0.42) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL3609510 | 0.83 | CHRNA7 (0.47) | CHRNA7CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657010-B2 | Substituted quinuclidines as alpha 7-nicotinic acetylcholine receptor activity modulators | NOVARTIS AG (CH) | 2017-05-23 | — | — | US | disclosed |
| US-20140057921-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA. 7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES | NOVARTIS AG (CH) | 2014-02-27 | — | — | US | disclosed |
| US-8609662-B2 | 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha. 7-nachr ligands for the treatment of CNS diseases | NOVARTIS AG (CH) | 2013-12-17 | — | — | US | disclosed |
| EP-2457911-A1 | 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha.7-nAChR ligands for the treatment of CNS diseases. | Novartis AG (CH) | 2012-05-30 | — | — | EP | disclosed |
| US-20100093746-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA. 7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES | NOVARTIS AG | 2010-04-15 | — | — | US | disclosed |
| US-20080194573-A1 | Psychological and neurodegenerative disorders; nicotinic acetylcholine receptors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1776360-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA.7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES. | Novartis AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006005608-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA.7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES | NOVARTIS AG (CH) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194573-A1 | Psychological and neurodegenerative disorders; nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA6 | CHRNA7 1/4885CHRNB2 11/4885CHRNB4 13/4885 |
| US-20100093746-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA. 7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES | CHRNA7, CHRNA5, CHRNA2 | CHRNA7 1/4885CHRNB2 11/4885CHRNB4 15/4885 |
| US-20140057921-A1 | 3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA. 7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES | CHRNA7, CHRNA5, CHRNA2 | CHRNA7 1/4885CHRNB2 11/4885CHRNB4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.